Acutus Medical (NASDAQ:AFIB – Get Free Report) and InspireMD (NYSE:NSPR – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.
Volatility and Risk
Acutus Medical has a beta of -0.75, meaning that its share price is 175% less volatile than the S&P 500. Comparatively, InspireMD has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500.
Profitability
This table compares Acutus Medical and InspireMD’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Acutus Medical | -272.74% | -311.64% | -11.57% |
| InspireMD | -413.96% | -69.42% | -57.68% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Acutus Medical | 0 | 0 | 0 | 0 | 0.00 |
| InspireMD | 0 | 0 | 2 | 0 | 3.00 |
InspireMD has a consensus target price of $4.50, indicating a potential upside of 148.62%. Given InspireMD’s stronger consensus rating and higher possible upside, analysts plainly believe InspireMD is more favorable than Acutus Medical.
Earnings & Valuation
This table compares Acutus Medical and InspireMD”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Acutus Medical | $7.16 million | 0.00 | -$81.66 million | ($0.11) | 0.00 |
| InspireMD | $7.78 million | 9.71 | -$19.92 million | ($0.84) | -2.15 |
InspireMD has higher revenue and earnings than Acutus Medical. InspireMD is trading at a lower price-to-earnings ratio than Acutus Medical, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
56.9% of Acutus Medical shares are held by institutional investors. Comparatively, 44.8% of InspireMD shares are held by institutional investors. 5.2% of Acutus Medical shares are held by insiders. Comparatively, 34.1% of InspireMD shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
InspireMD beats Acutus Medical on 9 of the 14 factors compared between the two stocks.
About Acutus Medical
Acutus Medical, Inc. designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is headquartered in Carlsbad, California.
About InspireMD
InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
Receive News & Ratings for Acutus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acutus Medical and related companies with MarketBeat.com's FREE daily email newsletter.
